Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00286494
Registration number
NCT00286494
Ethics application status
Date submitted
1/02/2006
Date registered
3/02/2006
Date last updated
3/02/2012
Titles & IDs
Public title
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
Query!
Secondary ID [1]
0
0
2005-004669-40
Query!
Secondary ID [2]
0
0
SYR-322-TZD-009
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Alogliptin and pioglitazone
Treatment: Drugs - Alogliptin and pioglitazone
Treatment: Drugs - Pioglitazone
Active Comparator: Placebo -
Experimental: Alogliptin 12.5 mg QD -
Experimental: Alogliptin 25 mg QD -
Treatment: Drugs: Alogliptin and pioglitazone
Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
Treatment: Drugs: Alogliptin and pioglitazone
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
Treatment: Drugs: Pioglitazone
Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.
Query!
Assessment method [1]
0
0
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.
Query!
Timepoint [1]
0
0
Baseline and Week 26.
Query!
Secondary outcome [1]
0
0
Change From Baseline in Glycosylated Hemoglobin (Week 4).
Query!
Assessment method [1]
0
0
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline.
Query!
Timepoint [1]
0
0
Baseline and Week 4.
Query!
Secondary outcome [2]
0
0
Change From Baseline in Glycosylated Hemoglobin (Week 8).
Query!
Assessment method [2]
0
0
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline.
Query!
Timepoint [2]
0
0
Baseline and Week 8.
Query!
Secondary outcome [3]
0
0
Change From Baseline in Glycosylated Hemoglobin (Week 12).
Query!
Assessment method [3]
0
0
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline.
Query!
Timepoint [3]
0
0
Baseline and Week 12.
Query!
Secondary outcome [4]
0
0
Change From Baseline in Glycosylated Hemoglobin (Week 16).
Query!
Assessment method [4]
0
0
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline.
Query!
Timepoint [4]
0
0
Baseline and Week 16.
Query!
Secondary outcome [5]
0
0
Change From Baseline in Glycosylated Hemoglobin (Week 20).
Query!
Assessment method [5]
0
0
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline.
Query!
Timepoint [5]
0
0
Baseline and Week 20.
Query!
Secondary outcome [6]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 1).
Query!
Assessment method [6]
0
0
The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline.
Query!
Timepoint [6]
0
0
Baseline and Week 1.
Query!
Secondary outcome [7]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 2).
Query!
Assessment method [7]
0
0
The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.
Query!
Timepoint [7]
0
0
Baseline and Week 2.
Query!
Secondary outcome [8]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 4).
Query!
Assessment method [8]
0
0
The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
Query!
Timepoint [8]
0
0
Baseline and Week 4.
Query!
Secondary outcome [9]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 8).
Query!
Assessment method [9]
0
0
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
Query!
Timepoint [9]
0
0
Baseline and Week 8.
Query!
Secondary outcome [10]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 12).
Query!
Assessment method [10]
0
0
The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline.
Query!
Timepoint [10]
0
0
Baseline and Week 12.
Query!
Secondary outcome [11]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 16).
Query!
Assessment method [11]
0
0
The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline.
Query!
Timepoint [11]
0
0
Baseline and Week 16.
Query!
Secondary outcome [12]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 20).
Query!
Assessment method [12]
0
0
The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline.
Query!
Timepoint [12]
0
0
Baseline and Week 20.
Query!
Secondary outcome [13]
0
0
Change From Baseline in Fasting Plasma Glucose (Week 26).
Query!
Assessment method [13]
0
0
The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline.
Query!
Timepoint [13]
0
0
Baseline and Week 26.
Query!
Secondary outcome [14]
0
0
Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose = 200 mg Per dL).
Query!
Assessment method [14]
0
0
The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study.
Query!
Timepoint [14]
0
0
26 Weeks.
Query!
Secondary outcome [15]
0
0
Number of Participants Requiring Rescue.
Query!
Assessment method [15]
0
0
The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study.
Query!
Timepoint [15]
0
0
26 Weeks.
Query!
Secondary outcome [16]
0
0
Change From Baseline in Fasting Proinsulin (Week 4).
Query!
Assessment method [16]
0
0
The change between the value of fasting proinsulin collected at week 4 and fasting proinsulin collected at baseline.
Query!
Timepoint [16]
0
0
Baseline and Week 4.
Query!
Secondary outcome [17]
0
0
Change From Baseline in Fasting Proinsulin (Week 8).
Query!
Assessment method [17]
0
0
The change between the value of fasting proinsulin collected at week 8 and fasting proinsulin collected at baseline.
Query!
Timepoint [17]
0
0
Baseline and Week 8.
Query!
Secondary outcome [18]
0
0
Change From Baseline in Fasting Proinsulin (Week 12).
Query!
Assessment method [18]
0
0
The change between the value of fasting proinsulin collected at week 12 and fasting proinsulin collected at baseline.
Query!
Timepoint [18]
0
0
Baseline and Week 12.
Query!
Secondary outcome [19]
0
0
Change From Baseline in Fasting Proinsulin (Week 16).
Query!
Assessment method [19]
0
0
The change between the value of fasting proinsulin collected at week 16 and fasting proinsulin collected at baseline.
Query!
Timepoint [19]
0
0
Baseline and Week 16.
Query!
Secondary outcome [20]
0
0
Change From Baseline in Fasting Proinsulin (Week 20).
Query!
Assessment method [20]
0
0
The change between the value of fasting proinsulin collected at week 20 and fasting proinsulin collected at baseline.
Query!
Timepoint [20]
0
0
Baseline and Week 20.
Query!
Secondary outcome [21]
0
0
Change From Baseline in Fasting Proinsulin (Week 26).
Query!
Assessment method [21]
0
0
The change between the value of fasting proinsulin collected at week 26 or final visit and fasting proinsulin collected at baseline.
Query!
Timepoint [21]
0
0
Baseline and Week 26.
Query!
Secondary outcome [22]
0
0
Change From Baseline in Insulin (Week 4).
Query!
Assessment method [22]
0
0
The change between the value of insulin collected at week 4 and insulin collected at baseline.
Query!
Timepoint [22]
0
0
Baseline and Week 4.
Query!
Secondary outcome [23]
0
0
Change From Baseline in Insulin (Week 8).
Query!
Assessment method [23]
0
0
The change between the value of insulin collected at week 8 and insulin collected at baseline.
Query!
Timepoint [23]
0
0
Baseline and Week 8.
Query!
Secondary outcome [24]
0
0
Change From Baseline in Insulin (Week 12).
Query!
Assessment method [24]
0
0
The change between the value of insulin collected at week 12 and insulin collected at baseline.
Query!
Timepoint [24]
0
0
Baseline and Week 12.
Query!
Secondary outcome [25]
0
0
Change From Baseline in Insulin (Week 16).
Query!
Assessment method [25]
0
0
The change between the value of insulin collected at week 16 and insulin collected at baseline.
Query!
Timepoint [25]
0
0
Baseline and Week 16.
Query!
Secondary outcome [26]
0
0
Change From Baseline in Insulin (Week 20).
Query!
Assessment method [26]
0
0
The change between the value of insulin collected at week 20 and insulin collected at baseline.
Query!
Timepoint [26]
0
0
Baseline and Week 20.
Query!
Secondary outcome [27]
0
0
Change From Baseline in Insulin (Week 26).
Query!
Assessment method [27]
0
0
The change between the value of insulin collected at week 26 and insulin collected at baseline.
Query!
Timepoint [27]
0
0
Baseline and Week 26.
Query!
Secondary outcome [28]
0
0
Change From Baseline in Proinsulin/Insulin Ratio (Week 4).
Query!
Assessment method [28]
0
0
The change between the ratio value of proinsulin and insulin collected at week 4 and the ratio value of proinsulin and insulin collected at baseline.
Query!
Timepoint [28]
0
0
Baseline and Week 4.
Query!
Secondary outcome [29]
0
0
Change From Baseline in Proinsulin/Insulin Ratio (Week 8).
Query!
Assessment method [29]
0
0
The change between the ratio value of proinsulin and insulin collected at week 8 and the ratio value of proinsulin and insulin collected at baseline.
Query!
Timepoint [29]
0
0
Baseline and Week 8.
Query!
Secondary outcome [30]
0
0
Change From Baseline in Proinsulin/Insulin Ratio (Week 12).
Query!
Assessment method [30]
0
0
The change between the ratio value of proinsulin and insulin collected at week 12 and the ratio value of proinsulin and insulin collected at baseline.
Query!
Timepoint [30]
0
0
Baseline and Week 12.
Query!
Secondary outcome [31]
0
0
Change From Baseline in Proinsulin/Insulin Ratio (Week 16).
Query!
Assessment method [31]
0
0
The change between the ratio value of proinsulin and insulin collected at week 16 and the ratio value of proinsulin and insulin collected at baseline.
Query!
Timepoint [31]
0
0
Baseline and Week 16.
Query!
Secondary outcome [32]
0
0
Change From Baseline in Proinsulin/Insulin Ratio (Week 20).
Query!
Assessment method [32]
0
0
The change between the ratio value of proinsulin and insulin collected at week 20 and the ratio value of proinsulin and insulin collected at baseline.
Query!
Timepoint [32]
0
0
Baseline and Week 20.
Query!
Secondary outcome [33]
0
0
Change From Baseline in Proinsulin/Insulin Ratio (Week 26).
Query!
Assessment method [33]
0
0
The change between the ratio value of proinsulin and insulin collected at week 26 or final visit and the ratio value of proinsulin and insulin collected at baseline.
Query!
Timepoint [33]
0
0
Baseline and Week 26.
Query!
Secondary outcome [34]
0
0
Change From Baseline in C-peptide (Week 4).
Query!
Assessment method [34]
0
0
The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline.
Query!
Timepoint [34]
0
0
Baseline and Week 4.
Query!
Secondary outcome [35]
0
0
Change From Baseline in C-peptide (Week 8).
Query!
Assessment method [35]
0
0
The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline.
Query!
Timepoint [35]
0
0
Baseline and Week 8.
Query!
Secondary outcome [36]
0
0
Change From Baseline in C-peptide (Week 12).
Query!
Assessment method [36]
0
0
The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline.
Query!
Timepoint [36]
0
0
Baseline and Week 12.
Query!
Secondary outcome [37]
0
0
Change From Baseline in C-peptide (Week 16).
Query!
Assessment method [37]
0
0
The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline.
Query!
Timepoint [37]
0
0
Baseline and Week 16.
Query!
Secondary outcome [38]
0
0
Change From Baseline in C-peptide (Week 20).
Query!
Assessment method [38]
0
0
The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline.
Query!
Timepoint [38]
0
0
Baseline and Week 20.
Query!
Secondary outcome [39]
0
0
Change From Baseline in C-peptide (Week 26).
Query!
Assessment method [39]
0
0
The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline.
Query!
Timepoint [39]
0
0
Baseline and Week 26.
Query!
Secondary outcome [40]
0
0
Number of Participants With Glycosylated Hemoglobin = 6.5%.
Query!
Assessment method [40]
0
0
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study.
Query!
Timepoint [40]
0
0
Baseline and Week 26.
Query!
Secondary outcome [41]
0
0
Number of Participants With Glycosylated Hemoglobin = 7.0%.
Query!
Assessment method [41]
0
0
The number of participants with a value for the percentage of glycosylated hemoglobin less (the percentage of hemoglobin that is bound to glucose) than or equal to 7.0% during the 26 week study.
Query!
Timepoint [41]
0
0
Baseline and Week 26.
Query!
Secondary outcome [42]
0
0
Number of Participants With Glycosylated Hemoglobin = 7.5%.
Query!
Assessment method [42]
0
0
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study.
Query!
Timepoint [42]
0
0
Baseline and Week 26.
Query!
Secondary outcome [43]
0
0
Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 0.5%.
Query!
Assessment method [43]
0
0
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study.
Query!
Timepoint [43]
0
0
Baseline and Week 26.
Query!
Secondary outcome [44]
0
0
Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 1.0%.
Query!
Assessment method [44]
0
0
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study.
Query!
Timepoint [44]
0
0
Baseline and Week 26.
Query!
Secondary outcome [45]
0
0
Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 1.5%.
Query!
Assessment method [45]
0
0
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study.
Query!
Timepoint [45]
0
0
Baseline and Week 26.
Query!
Secondary outcome [46]
0
0
Number of Participants With Glycosylated Hemoglobin Decrease From Baseline = 2.0%.
Query!
Assessment method [46]
0
0
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study.
Query!
Timepoint [46]
0
0
Baseline and Week 26.
Query!
Secondary outcome [47]
0
0
Change From Baseline in Body Weight (Week 8).
Query!
Assessment method [47]
0
0
The change between Body Weight measured at week 8 and Body Weight measured at baseline.
Query!
Timepoint [47]
0
0
Baseline and Week 8.
Query!
Secondary outcome [48]
0
0
Change From Baseline in Body Weight (Week 12).
Query!
Assessment method [48]
0
0
The change between Body Weight measured at week 12 and Body Weight measured at baseline.
Query!
Timepoint [48]
0
0
Baseline and Week 12.
Query!
Secondary outcome [49]
0
0
Change From Baseline in Body Weight (Week 20).
Query!
Assessment method [49]
0
0
The change between Body Weight measured at week 20 and Body Weight measured at baseline.
Query!
Timepoint [49]
0
0
Baseline and Week 20.
Query!
Secondary outcome [50]
0
0
Change From Baseline in Body Weight (Week 26).
Query!
Assessment method [50]
0
0
The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline.
Query!
Timepoint [50]
0
0
Baseline and Week 26.
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- Diagnosis of type 2 diabetes mellitus currently treated with a thiazolidinedione
either alone or in combination with metformin or a sulfonylurea but who are
experiencing inadequate glycemic control. The subject should have received the
thiazolidinedione therapy (rosiglitazone or pioglitazone) either alone or in
combination with metformin or a sulfonylurea for at least the 3 months prior to
Screening and must have been on a stable dose for all their antidiabetic treatments
for at least the month prior to Screening.
- No treatment with antidiabetic agents other than a thiazolidinedione alone or in
combination with either metformin or a sulfonylurea within the 3 months prior to
Screening. (Exception: if a subject has received other antidiabetic therapy for less
than 7 days within the 3 months prior to Screening.)
- Body mass index greater than or equal to 23 kg/m2 and less than or equal to 45 kg/m2
- Fasting C-peptide concentration greater than or equal to 0.8 ng per mL. (If this
screening criterion is not met, the subject still qualifies if C-peptide is greater
than or equal to 1.5 ng per mL after a challenge test.)
- Glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive.
- If regular use of other, non-excluded medications, must be on a stable dose for at
least the 4 weeks prior to Screening. However, as needed use of prescription or
over-the-counter medications is allowed at the discretion of the investigator.
- Systolic blood pressure less than or equal to 180 mm Hg and diastolic pressure less
than or equal to 110 mm Hg.
- Hemoglobin greater than or equal to 12 g per dL for males and greater than or equal
to10 g per dL for females.
- Alanine aminotransferase less than or equal to 2.5 times the upper limit of normal.
- Serum creatinine less than or equal to 2.0 mg per dL.
- Thyroid-stimulating hormone level less than or equal to the upper limit of the normal
range and the subject is clinically euthyroid.
- Neither pregnant nor lactating.
- Female subjects of childbearing potential must be practicing adequate contraception.
Adequate contraception must be practiced for the duration of participation in the
study.
- Able and willing to monitor their own blood glucose concentrations with a home glucose
monitor.
- No major illness or debility that in the investigator's opinion prohibits the subject
from completing the study.
- Able and willing to provide written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- Urine albumin to creatinine ratio of greater than 1000 µg per mg at Screening. If
elevated, the subject may be rescreened within 1 week.
- History of cancer, other than squamous cell or basal cell carcinoma of the skin, that
has not been in full remission for at least 5 years prior to Screening. (A history of
treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II
is allowed.)
- History of laser treatment for proliferative diabetic retinopathy within the 6 months
prior to Screening.
- History of treated diabetic gastric paresis.
- New York Heart Association Class III or IV heart failure regardless of therapy.
Currently treated subjects who are stable at Class I or II are candidates for the
study.
- History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or
myocardial infarction within the 6 months prior to Screening
- History of any hemoglobinopathy that may affect determination of glycosylated
hemoglobin.
- History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
- History of a psychiatric disorder that will affect the subject's ability to
participate in the study.
- History of angioedema in association with use of angiotensin-converting enzyme
inhibitors or angiotensin-II receptor inhibitors.
- History of alcohol or substance abuse within the 2 years prior to Screening.
- Receipt of any investigational drug within the 30 days prior to Screening or a history
of receipt of an investigational antidiabetic drug within the 3 months prior to
Screening.
- Prior treatment in an investigational study of alogliptin.
- Excluded Medications:
- Treatment with antidiabetic agents other than a thiazolidinedione alone or in
combination with either metformin or a sulfonylurea is not allowed within the 3
months prior to Screening and through the completion of the
end-of-treatment/early termination procedures.
- Treatment with weight-loss drugs, any investigational antidiabetics, or oral or
systemically injected glucocorticoids is not allowed from 3 months prior to
randomization through the completion of the end-of-treatment/early termination
procedures. Inhaled corticosteroids are allowed.
Subjects must not take any medications, including over-the-counter products, without first
consulting with the investigator.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2007
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
493
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Multiple Cities
Query!
Recruitment postcode(s) [1]
0
0
- Multiple Cities
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Hawaii
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Idaho
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Illinois
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Indiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Kentucky
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oklahoma
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oregon
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Vermont
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Multiple Cities
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Multiple Cities
Query!
Country [30]
0
0
Czech Republic
Query!
State/province [30]
0
0
Multiple Cities
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Multiple Cities
Query!
Country [32]
0
0
Guatemala
Query!
State/province [32]
0
0
Multiple Cities
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Multiple Cities
Query!
Country [34]
0
0
India
Query!
State/province [34]
0
0
Multiple Cities
Query!
Country [35]
0
0
Mexico
Query!
State/province [35]
0
0
Multiple Cities
Query!
Country [36]
0
0
Netherlands
Query!
State/province [36]
0
0
Multiple Cities
Query!
Country [37]
0
0
New Zealand
Query!
State/province [37]
0
0
Multiple Cities
Query!
Country [38]
0
0
Peru
Query!
State/province [38]
0
0
Multiple Cities
Query!
Country [39]
0
0
South Africa
Query!
State/province [39]
0
0
Multiple Cities
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Takeda
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily
(QD), combined with pioglitazone in adults with type 2 diabetes mellitus
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00286494
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
VP Biological Sciences
Query!
Address
0
0
Takeda
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00286494
Download to PDF